{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T02:17:44Z","timestamp":1767665864485},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T00:00:00Z","timestamp":1324512000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0028955","type":"journal-article","created":{"date-parts":[[2011,12,22]],"date-time":"2011-12-22T21:38:38Z","timestamp":1324589918000},"page":"e28955","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dynamics of Resistance Development to Imatinib under Increasing Selection Pressure: A Combination of Mathematical Models and In Vitro Data"],"prefix":"10.1371","volume":"6","author":[{"given":"Benjamin","family":"Werner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Traulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Balabanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,12,22]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (stim) trial.","author":"FX Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine uorescence and giemsa staining.","volume":"243","author":"JD Rowley","year":"1973","journal-title":"Nature"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"M Deininger","year":"2000","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"BJ Druker","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of amn107, a selective inhibitor of native and mutant bcr-abl.","volume":"7","author":"E Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel abl kinase inhibitor.","volume":"305","author":"NP Shah","year":"2004","journal-title":"Science"},{"key":"ref7","article-title":"Safety and efficacy of bosutinib (ski-606) in chronic phase philadelphia chromosome-positive cml patients with resistance or intolerance to imatinib.","volume":"355594","author":"J Cortes","year":"2011","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"900","DOI":"10.3324\/haematol.2009.015271","article-title":"Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.","volume":"95","author":"T Lenaerts","year":"2010","journal-title":"Haematologica"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"G Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"326","author":"H Kantarjian","year":"2010","journal-title":"New Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.","volume":"110","author":"T O'Hare","year":"2007","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1182\/asheducation-2009.1.461","article-title":"Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.","author":"D Bixby","year":"2009","journal-title":"Hematology American Society of Hematology Education Program Book"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4161\/cc.10.2.14537","article-title":"Impact of bcr-abl mutations on patients with chronic myeloid leukemia.","volume":"10","author":"A Hochhaus","year":"2011","journal-title":"Cell Cycle"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.4.4.1702","article-title":"Kinase-addiction and bi-phasic sensitivity-resistance of bcr-abl- and raf-1-expressing cells to imatinib and geldanamycin.","volume":"4","author":"ZN Demidenko","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"Ap24534, a pan-bcr-abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutationbased resistance.","volume":"16","author":"T O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012300","article-title":"Optimizing combination therapies with existing and future cml drugs.","volume":"5","author":"AA Katouli","year":"2010","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1158\/0008-5472.CAN-08-1959","article-title":"Combination therapies against chronic myeloid leukemia: shortterm versus long-term strategies.","volume":"69","author":"NL Komarova","year":"2009","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e4423","DOI":"10.1371\/journal.pone.0004423","article-title":"Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia.","volume":"4","author":"NL Komarova","year":"2009","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e19164","DOI":"10.1371\/journal.pone.0019164","article-title":"Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor danusertib in bcr-abl-positive cells in vitro.","volume":"6","author":"S Balabanov","year":"2011","journal-title":"PLoS ONE"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory pi3- kinase\/akt\/mtor activation regulates imatinib resistance development.","volume":"19","author":"A Burchert","year":"2005","journal-title":"Leukemia"},{"key":"ref21","doi-asserted-by":"crossref","DOI":"10.1016\/S0076-6879(79)58132-4","article-title":"Measurement of growth and viability of cells in culture.","volume":"58","author":"MK Patterson","year":"1979","journal-title":"Methods Enzymol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2005-03-037648","article-title":"Hypusination of eukaryotic initiation factor 5a (eif5a): a novel therapeutic target in bcr-abl-positive leukemias identified by a proteomics approach.","volume":"109","author":"S Balabanov","year":"2007","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","article-title":"Generalized equations for the analysis of inhibitions of michaelis-menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors.","volume":"115","author":"TC Chou","year":"1981","journal-title":"Eur J Biochem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (rq-pcr) - a europe against cancer program.","volume":"17","author":"E Beillard","year":"2003","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a europe against cancer program.","volume":"17","author":"J Gabert","year":"2003","journal-title":"Leukemia"},{"key":"ref26","article-title":"The Statistical Processes of Evolutionary Theory.","author":"PAP Moran","year":"1962"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.2307\/j.ctvjghw98","article-title":"Evolutionary Dynamics.","author":"MA Nowak","year":"2006"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0022-5193(02)93112-7","article-title":"Unifying evolutionary dynamics.","volume":"219","author":"KM Page","year":"2002","journal-title":"J Theor Biol"},{"key":"ref29","first-page":"65","article-title":"Explicationes, annotationes, additiones ad ea, quae in actis sup. anni de curva elastica, isochrona paracentrica, velaria, hinc inde memorata, paratim controversa legundur; ubi de linea mediarum directionum, alliisque novis.","volume":"1","author":"J Bernoulli","year":"1695","journal-title":"Acta Eruditorum"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (sti571, glivec): a targeted oncoprotein strikes back.","volume":"17","author":"N von Bubnoff","year":"2003","journal-title":"Leukemia"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/sj.leu.2402409","article-title":"Sti-571 must select for drug-resistant cells but \u2018no cell breathes fire out of its nostrils like a dragon\u2019.","volume":"16","author":"MV Blagosklonny","year":"2002","journal-title":"Leukemia"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/genetics\/148.4.1667","article-title":"Rates of spontaneous mutation.","volume":"148","author":"JW Drake","year":"1998","journal-title":"Genetics"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1126\/science.1191125","article-title":"Increased mutagenesis and unique mutation signature associated with mitotic gene conversion.","volume":"329","author":"WM Hicks","year":"2010","journal-title":"Science"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.4161\/cc.4.12.2261","article-title":"Bcr-abl kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?","volume":"4","author":"T Lange","year":"2005","journal-title":"Cell Cycle"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","article-title":"Expression of a src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.","volume":"285","author":"T Pene-Dumitrescu","year":"2010","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinib-resistant bcr-abl mutation-negative leukemia and persistent activation of lyn kinase.","volume":"100","author":"J Wu","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/j.1476-5381.2009.00345.x","article-title":"Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.","volume":"158","author":"J Klawitter","year":"2009","journal-title":"Br J Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1158\/1078-0432.CCR-08-3291","article-title":"Abnormalities in glucose uptake and metabolism in imatinib-resistant human bcr-abl-positive cells.","volume":"15","author":"DJ Kominsky","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3934\/mbe.2011.8.289","article-title":"Mathematical modeling of cyclic treatments of chronic myeloid leukemia.","volume":"8","author":"NL Komarova","year":"2011","journal-title":"Nath Biosci Eng"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.pone.0000002","article-title":"Allometric scaling of the active hematopoietic stem cell pool across mammals.","volume":"1","author":"D Dingli","year":"2006","journal-title":"PLoS One"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"18983","DOI":"10.1073\/pnas.1107621108","article-title":"Evolutionary dynamics of feedback escape and the development of stem-cell-driven cancers.","author":"A Rodriguez-Brenes","year":"2011","journal-title":"Proc Natl Acad Sc"},{"key":"ref42","article-title":"Dynamics of mutant cells in hierarchical organized tissues.","author":"B Werner","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"713","DOI":"10.18632\/oncotarget.333","article-title":"Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.","author":"JC Chomel","year":"2011","journal-title":"Oncotarget"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.18632\/oncotarget.119","article-title":"Role of pten in leukemia stem cells.","volume":"1","author":"C Peng","year":"2010","journal-title":"Oncotarget"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.18632\/aging.100244","article-title":"The age of the target cell affects b-cell leukaemia malignancy.","author":"C Vicente-Due\u00f1as","year":"2010","journal-title":"Aging (Albany NY)"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4161\/cc.10.10.15518","article-title":"Explaining the in vitro and in vivo differences in leukemia therapy.","volume":"10","author":"T Lenaerts","year":"2011","journal-title":"Cell Cycle"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jnci\/djk150","article-title":"Instability of bcr-abl gene in primary and cultured chronic myeloid leukemia stem cells.","volume":"99","author":"X Jiang","year":"2007","journal-title":"Journal of The National Cancer Institute"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of bcr-abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.","volume":"26","author":"IJ Griswold","year":"2006","journal-title":"Molecular and Cellular Biology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"19466","DOI":"10.1073\/pnas.0609239103","article-title":"Phosphorylation of the atpbinding loop directs oncogenicity of drug-resistant bcr-abl mutants.","volume":"103","author":"BJ Skaggs","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant bcr-ablpositive clones after cessation of tyrosine kinase inhibitor therapy.","volume":"96","author":"B Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3816\/CLK.2008.n.017","article-title":"Chronic myeloid leukemia: origin, development, response to therapy, and relapse.","volume":"2","author":"D Dingli","year":"2008","journal-title":"Clinical Leukemia"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.mib.2006.07.002","article-title":"The biological cost of mutational antibiotic resistance: any practical conclusions?","volume":"9","author":"DI Andersson","year":"2006","journal-title":"Current Opinion in Microbiology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrmicro2319","article-title":"Antibiotic resistance and its cost: is it possible to reverse resistance?","volume":"8","author":"DI Andersson","year":"2010","journal-title":"Nature Reviews Microbiology"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0028955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T21:33:27Z","timestamp":1640122407000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0028955"}},"subtitle":[],"editor":[{"given":"Mikhail V.","family":"Blagosklonny","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,12,22]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2011,12,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0028955","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,22]]}}}